SC 13G 1 tm226056d1_sc13g.htm SC 13G

Securities and Exchange Commission

Washington, D.C. 20549

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. )*

Immuneering Corporation

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

45254E107

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45254E107

Schedule 13G

Page 1 of 4

1	Names of Reporting Persons Benjamin J. Zeskind
2	Check the Appropriate Box if a Member of a Group	(a) ¨ (b) ¨
3	SEC Use Only
4	Citizenship or Place of Organization United States

Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 2,462,352
	6	Shared Voting Power 894,927
	7	Sole Dispositive Power 2,462,352
	8	Shared Dispositive Power 894,927

9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,357,279
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable
11	Percent of Class Represented by Amount in Row 9 12.7%
12	Type of Reporting Person IN

CUSIP No. 45254E107

Schedule 13G

Page 2 of 4

ITEM 1.

(a)

Name of Issuer:

Immuneering Corporation (the “Issuer”).

(b)

Address of Issuer’s Principal Executive Offices:

245 Main St., Second Floor, Cambridge, MA 02142

ITEM 2.

(a)

Name of Person Filing:

This statement is filed on behalf of Benjamin J. Zeskind (the “Reporting Person”).

(b)

Address or Principal Business Office:

The principal business address of the Reporting Person is c/o Immuneering Corporation, 245 Main St., Second Floor, Cambridge, MA 02142.

(c)

Citizenship of each Reporting Person is:

The Reporting Person is a citizen of the United States.

(d)

Title of Class of Securities:

Class A common stock, par value $0.001 per share (“Class A Common Stock”).

(e)

CUSIP Number:

45254E107

ITEM 3.

Not applicable.

ITEM 4.

Ownership.

(a-c)

The ownership information presented below represents beneficial ownership of Class A Common Stock of the Issuer as of December 31, 2021, based upon 26,320,199 shares of Class A Common Stock outstanding as of December 31, 2021.

CUSIP No. 45254E107

Schedule 13G

Page 3 of 4

Reporting Person		Amount beneficially owned		Percent of class:		Sole power to vote or to direct the vote:		Shared power to vote or to direct the vote:		Sole power to dispose or to direct the disposition of:		Shared power to dispose or to direct the disposition of:
Benjamin J. Zeskind		3,357,279		12.7%		2,462,352		894,927		2,462,352		894,927

The Reporting Person is the beneficial owner of 3,357,279 shares of Class A Common Stock, which consist of (i) 2,252,352 shares of Class A Common Stock held of record by the Reporting Person; (ii) 210,000 shares of Class A Common Stock underlying stock options held of record by the Reporting Person that are exercisable prior to March 1, 2021; and (iii) 894,927 shares of Class A Common Stock held of record by the Benjamin J. Zeskind 2020 Family Trust, of which the Reporting Person’s spouse serves as sole trustee.

ITEM 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

ITEM 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

ITEM 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

ITEM 8.

Identification and Classification of Members of the Group.

Not applicable.

ITEM 9.

Notice of Dissolution of Group.

Not applicable.

ITEM 10.

Certification.

Not applicable.

CUSIP No. 45254E107

Schedule 13G

Page 4 of 4

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 10, 2022

	Benjamin J. Zeskind

	/s/ Benjamin J. Zeskind

SEC Form SC 13G filed by Immuneering Corporation